Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The Company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies, SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies, and phage display technologies. It is also developing checkpoint modulating antibody candidates. In addition, the Company develops cancer and tumor vaccine programs and a saponin-based vaccine adjuvant for the treatment of malaria and shingles.

Type
Public
HQ
Lexington, US
Founded
1994
Size (employees)
255 (est)
Agenus was founded in 1994 and is headquartered in Lexington, US
Report incorrect company information

Key People/Management at Agenus

Garo Armen

Garo Armen

PhD, Chairman and CEO
Jennifer Buell

Jennifer Buell

PhD, Chief Communications and External Affairs Officer
Ozer Baysal

Ozer Baysal

Chief Commercial Officer and Head of Human Resources
Michael Plater

Michael Plater

PhD, Chief Business Officer
Alex Duncan

Alex Duncan

PhD, Chief Technology Officer and Head of Research
Christian Cortis

Christian Cortis

PhD, Chief Strategy Officer
Show more

Agenus Office Locations

Agenus has offices in Cambridge, Berkeley, New York and Lexington
Lexington, US (HQ)
3 Forbes Road
Berkeley, US
793 Heinz Ave
New York, US
149 Fifth Ave. Suite 500
Cambridge, GB
315 Science Park Milton Road
Show all (4)
Report incorrect company information

Agenus Financials and Metrics

Agenus Financials

Agenus's revenue was reported to be $42.88 m in FY, 2017
USD

Revenue (Q1, 2018)

1.6 m

Net income (Q1, 2018)

(54.3 m)

EBIT (Q1, 2018)

(41.7 m)

Market capitalization (14-Jun-2018)

291.2 m

Closing share price (14-Jun-2018)

2.8

Cash (31-Mar-2018)

52.3 m

EV

251.8 m
Agenus's current market capitalization is $291.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3 m7 m24.8 m22.6 m42.9 m

Revenue growth, %

129%256%(9%)

General and administrative expense

33.7 m

R&D expense

42.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

736 k720.9 k3.1 m1.6 m4 m6.4 m6.8 m6 m6.6 m4.4 m27 m4.2 m1.6 m

General and administrative expense

3.6 m5.2 m5.8 m4.9 m5.5 m8 m6.4 m9.2 m7.1 m8.1 m7.8 m8.1 m8.9 m

R&D expense

3.9 m4.5 m5.2 m5.3 m9.2 m24.8 m18.5 m5.8 m6.6 m4.4 m27 m4.2 m29.4 m

Operating expense total

7.5 m9.6 m11.1 m10.2 m14.7 m32.8 m24.9 m15 m13.7 m12.6 m34.7 m12.3 m38.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

27.4 m25.7 m136.7 m71.4 m60.2 m

Accounts Receivable

1.2 k9.8 m11.4 m1.1 m

Inventories

95.7 k88.2 k88.2 k79.5 k

Current Assets

28.2 m42.7 m184.1 m91.3 m73.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

30.2 m73.5 m48.3 m38.4 m79.3 m124.7 m184.1 m78.3 m73.4 m75.4 m113.9 m81.8 m52.3 m

Accounts Receivable

1.1 k2.5 m4.1 m7.3 m10.2 m9.4 m10.3 m6.8 m3.9 m1.1 m

Inventories

3.3 k95.7 k95.7 k88.2 k88.2 k88.2 k88.2 k88.2 k88.2 k87.5 k87 k62.2 k

Current Assets

30.9 m75.3 m67 m55.2 m85.2 m146.3 m208.9 m161.6 m136.1 m109.5 m138 m110.7 m65.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(30.1 m)(42.5 m)(87.9 m)(127 m)(120.7 m)

Depreciation and Amortization

586.3 k1.6 m2 m4.9 m6 m

Inventories

16 k(95.7 k)7.5 k7.5 k8.7 k

Accounts Payable

189.6 k(45.9 k)2.7 m419.7 k1.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(24.3 m)(357.5 k)(8.4 m)(16.5 m)(18.7 m)(59.2 m)(13.1 m)(31.8 m)(28.3 m)(40.8 m)(17.1 m)(54.3 m)

Depreciation and Amortization

448.2 k266.5 k589.4 k1 m445.5 k885.5 k1.6 m

Inventories

12.7 k(95.7 k)(95.7 k)7.5 k7.5 k88.2 k88.2 k88.2 k88.2 k87.5 k17.3 k

Accounts Payable

(269.4 k)184 k(562.1 k)35.2 k2.3 m797.8 k3.1 m2.5 m5 m3.3 m4.8 m(2.8 m)
USDY, 2018

EV/EBIT

-6 x

EV/CFO

-6.3 x

Financial Leverage

-1.2 x
Show all financial metrics
Report incorrect company information

Agenus Online and Social Media Presence

Embed Graph
Report incorrect company information

Agenus News and Updates

Vaccine Adjuvants Market 2018-2023 Trend | Whooping Growth of 10.1% with CSL Ltd, Agenus Inc, Invivogen, Avanti Polar Lipids Inc

Vaccine Adjuvants Market Information: By Type (Pathogen Components, Particulate Adjuvants, others), By Route of Administration (Oral, Intramuscular, Subcutaneous, and Intradermal), and By End Users (Pediatric, Adult) - Global Forecast Till 2023 Posted via Industry Today. Follow us on Twitter @Indust…

Research Focused on the Vaccine Adjuvants Market Forecast up to 2025

Vaccines adjuvants market is expected to be driven by increasing prevalence of conditions such as, allergy, HIV and cancer. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information